NCT06642623View on ClinicalTrials.gov

A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients

PHASE4RecruitingINTERVENTIONAL
Enrollment

2,862

Participants

Timeline

Start Date

January 22, 2024

Primary Completion Date

September 30, 2029

Study Completion Date

December 31, 2030

Conditions
Diabetes Mellitus, Type 2Cardiovascular DiseasesKidney Diseases
Interventions
DRUG

Enavogliflozin

The dosage and administration method are determined according to the investigator's judgment, considering the drug's approval requirements and the medical condition of the study participants.

DRUG

Dapagliflozin or Empagliflozin

The dosage and administration method are determined according to the investigator's judgment, considering the drug's approval requirements and the medical condition of the study participants.

Trial Locations (1)

03722

RECRUITING

Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER